These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 31351413)

  • 1. The role of complement in IgA nephropathy.
    Tortajada A; Gutierrez E; Pickering MC; Praga Terente M; Medjeral-Thomas N
    Mol Immunol; 2019 Oct; 114():123-132. PubMed ID: 31351413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of complement in IgA nephropathy.
    Daha MR; van Kooten C
    J Nephrol; 2016 Feb; 29(1):1-4. PubMed ID: 26567162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges.
    Gutiérrez E; Carvaca-Fontán F; Luzardo L; Morales E; Alonso M; Praga M
    Nephron; 2020; 144(11):555-571. PubMed ID: 32818944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease.
    Roos A; Rastaldi MP; Calvaresi N; Oortwijn BD; Schlagwein N; van Gijlswijk-Janssen DJ; Stahl GL; Matsushita M; Fujita T; van Kooten C; Daha MR
    J Am Soc Nephrol; 2006 Jun; 17(6):1724-34. PubMed ID: 16687629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy.
    Zhu L; Guo WY; Shi SF; Liu LJ; Lv JC; Medjeral-Thomas NR; Lomax-Browne HJ; Pickering MC; Zhang H
    Kidney Int; 2018 Jul; 94(1):150-158. PubMed ID: 29759419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.
    Rizk DV; Maillard N; Julian BA; Knoppova B; Green TJ; Novak J; Wyatt RJ
    Front Immunol; 2019; 10():504. PubMed ID: 30941137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement in IgA Nephropathy: The Role of Complement in the Pathogenesis, Diagnosis, and Future Management of IgA Nephropathy.
    Medjeral-Thomas NR; O'Shaughnessy MM
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):111-119. PubMed ID: 32553243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement system is overactivated in patients with IgA nephropathy after COVID-19.
    Guo WY; Wang GQ; Kong LQ; Sun LJ; Xu XY; Cheng WR; Dong HR; Cheng H
    Clin Immunol; 2024 Jun; 263():110232. PubMed ID: 38701960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of secretory IgA and complement in IgA nephropathy.
    Oortwijn BD; Eijgenraam JW; Rastaldi MP; Roos A; Daha MR; van Kooten C
    Semin Nephrol; 2008 Jan; 28(1):58-65. PubMed ID: 18222347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of podocyte injury in IgA nephropathy.
    Menon MC; Chuang PY; He JC
    Contrib Nephrol; 2013; 181():41-51. PubMed ID: 23689566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot and comparative study between pathological and serological levels of immunoglobulin and complement among three kinds of primary glomerulonephritis.
    Dong J; Peng T; Gao J; Jia X; Yan G; Wang Y
    BMC Immunol; 2018 Jun; 19(1):18. PubMed ID: 29925312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement activation is associated with crescent formation in IgA nephropathy.
    Itami H; Hara S; Samejima K; Tsushima H; Morimoto K; Okamoto K; Kosugi T; Kawano T; Fujiki K; Kitada H; Hatakeyama K; Tsuruya K; Ohbayashi C
    Virchows Arch; 2020 Oct; 477(4):565-572. PubMed ID: 32300880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgA production and tonsillar focal infection in IgA nephropathy.
    Meng H; Ohtake H; Ishida A; Ohta N; Kakehata S; Yamakawa M
    J Clin Exp Hematop; 2012; 52(3):161-70. PubMed ID: 23269075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function.
    Onda K; Ohsawa I; Ohi H; Tamano M; Mano S; Wakabayashi M; Toki A; Horikoshi S; Fujita T; Tomino Y
    BMC Nephrol; 2011 Nov; 12():64. PubMed ID: 22111871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complement system in IgAN: mechanistic context for therapeutic opportunities.
    Duval A; Caillard S; Frémeaux-Bacchi V
    Nephrol Dial Transplant; 2023 Nov; 38(12):2685-2693. PubMed ID: 37385820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of severity of murine IgA nephropathy by glomerular complement activation by aberrantly glycosylated IgA and immune complexes.
    Hashimoto A; Suzuki Y; Suzuki H; Ohsawa I; Brown R; Hall S; Tanaka Y; Novak J; Ohi H; Tomino Y
    Am J Pathol; 2012 Oct; 181(4):1338-47. PubMed ID: 22871574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into the pathogenesis of IgA nephropathy.
    Floege J; Moura IC; Daha MR
    Semin Immunopathol; 2014 Jul; 36(4):431-42. PubMed ID: 24442210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy.
    Oortwijn BD; Roos A; Royle L; van Gijlswijk-Janssen DJ; Faber-Krol MC; Eijgenraam JW; Dwek RA; Daha MR; Rudd PM; van Kooten C
    J Am Soc Nephrol; 2006 Dec; 17(12):3529-39. PubMed ID: 17050773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy.
    Medjeral-Thomas NR; Lomax-Browne HJ; Beckwith H; Willicombe M; McLean AG; Brookes P; Pusey CD; Falchi M; Cook HT; Pickering MC
    Kidney Int; 2017 Oct; 92(4):942-952. PubMed ID: 28673452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crucial Role of AIM/CD5L in the Development of Glomerular Inflammation in IgA Nephropathy.
    Takahata A; Arai S; Hiramoto E; Kitada K; Kato R; Makita Y; Suzuki H; Nakata J; Araki K; Miyazaki T; Suzuki Y
    J Am Soc Nephrol; 2020 Sep; 31(9):2013-2024. PubMed ID: 32611589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.